|
ナカイ ヨウスケ
NAKAI Yousuke
中井 陽介 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Clinical Characteristics of Late-Onset (≥ 65 Years) Ulcerative Colitis: A Single-Center Retrospective Study |
| 掲載誌名 | 正式名：Gastroenterology research and practice 略 称：Gastroenterol Res Pract ISSNコード：16876121/16876121 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 2026,pp.8860301 |
| 著者・共著者 | ITO Ayumi, KOROKU Miki, MURASUGI Shun, YONEZAWA Maria, OOMORI Teppei, NAKAMURA Shinichi, TOKUSHIGE Katsutoshi, NAKAI Yosuke |
| 担当区分 | 最終著者 |
| 発行年月 | 2026/01 |
| 概要 | BACKGROUND:Late-onset ulcerative colitis (UC) has become prevalent in recent years. The differences between late-onset, middle aged-onset, and early-onset UC have not been fully elucidated.METHODS:The clinical characteristics, steroid side effects, remission rates, and surgical rates of UC patients were retrospectively studied. Patients were allocated to three groups according to age at diagnosis: late-onset group (≥ 65 years), middle aged-onset (50-64 years), and early-onset group (≤ 49 years).RESULTS:Clinical characteristics such as admission age, duration of disease, history of cancer, days to diagnosis, clinical activity on admission, hemoglobin level on admission, and steroid use were significantly different between the three groups. The side effects of steroids were significantly more common in the late-onset group. The remission induction rates differed significantly between the three groups: 67.7%, 71.7%, and 83.6% in the late-onset, middle aged-onset, and early-onset groups. Surgery rates were significantly higher in the late-onset group: Surgery rates in the late-onset, middle aged-onset, and early-onset groups were 14.2%, 3.4%, and 3.4% at 12 months of diagnosis, and 23.8%, 10.3%, and 4.2% at 24 months of diagnosis.CONCLUSIONS:In conclusion, remission rates were low and surgical rates were higher with increasing age of onset. In addition, steroid-related side effects increased with age. It was possible that late-onset UC may have a different pathogenesis and be resistant to treatment. |
| DOI | 10.1155/grp/8860301 |
| PMID | 41607563 |